AB
RYTM icon

Amalgamated Bank’s Rhythm Pharmaceuticals RYTM Stock Holding History

Amalgamated Bank’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,663
Closed -$178K – 2595
2025
Q4 		$178K Sell
1,663
-30
-2% -$3.18K ﹤0.01% 1595
2025
Q3 		$171K Sell
1,693
-188
-10% -$17.5K ﹤0.01% 1606
2025
Q2 		$119K Hold
1,881
– – ﹤0.01% 1670
2025
Q1 		$100K Buy
1,881
+6
+0.3% +$333 ﹤0.01% 1679
2024
Q4 		$105K Hold
1,875
– – ﹤0.01% 1694
2024
Q3 		$98K Hold
1,875
– – ﹤0.01% 1715
2024
Q2 		$77K Buy
1,875
+60
+3% +$2.4K ﹤0.01% 1768
2024
Q1 		$79K Sell
1,815
-5,458
-75% -$239K ﹤0.01% 1768
2023
Q4 		$334K Sell
7,273
-516
-7% -$16.3K ﹤0.01% 1600
2023
Q3 		$179K Hold
7,789
– – ﹤0.01% 1827
2023
Q2 		$128K Buy
+7,789
New +$141K ﹤0.01% 1986
2022
Q2 		– Sell
-5,326
Closed -$61K – 3178
2022
Q1 		$61K Buy
+5,326
New +$46.7K ﹤0.01% 2376

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Amalgamated Bank's RYTM Position: Q1 2026 in Review

Amalgamated Bank sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1,663 shares — an estimated $178K sold.

Amalgamated Bank first reported a position in RYTM in Q1 2022 and held it in 12 quarters. The position peaked at $334K in Q4 2023. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Amalgamated Bank reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,663 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $178K.
  • Amalgamated Bank first reported a position in Rhythm Pharmaceuticals in Q1 2022 and held it in 12 quarters.
  • Amalgamated Bank's Rhythm Pharmaceuticals position peaked at $334K in Q4 2023.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.